Efficacy of crizotinib retreatment after crizotinib-related interstitial lung disease in a patient with ROS1-rearranged advanced lung adenocarcinoma: A case report and potential crizotinib retreatment strategy

Crizotinib is an oral selective small-molecular tyrosine kinase inhibitor (TKI) that suppress the activity of anaplastic lymphoma kinase (ALK) and ROS1 kinases, as well as mesenchymal-epithelial transition. The cumulative clinical trials in patients with advanced ALK- or ROS1-rearrangement NSCLC ind...

Descripción completa

Detalles Bibliográficos
Autores principales: Ryu, Woo Kyung, Cha, Hyungkeun, Park, Mi Hwa, Kim, Jung Soo, Choi, Jeong-Seok, Kim, Lucia, Lee, Kyung-Hee, Nam, Hae-Seong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625112/
https://www.ncbi.nlm.nih.gov/pubmed/36330497
http://dx.doi.org/10.3389/fonc.2022.900966

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625112/
https://www.ncbi.nlm.nih.gov/pubmed/36330497
http://dx.doi.org/10.3389/fonc.2022.900966

Ejemplares similares